Download PDF
Semin Thromb Hemost 2013; 39(02): 127-140
DOI: 10.1055/s-0032-1333537
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Comprehensive Update on the Prevention and Treatment of Venous Thromboembolism in Cancer Patients

Vicky Tagalakis
1   Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
,
Caitlin Wharin
1   Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
,
Susan R. Kahn
1   Lady Davis Institute for Medical Research, Centre for Clinical Epidemiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
› Author Affiliations
Further Information

Publication History

Publication Date:
05 February 2013 (online)

    Permissions and Reprints

Abstract

Patients with cancer are at increased risk for venous thromboembolism (VTE). Prolonged medical hospitalization, extensive surgeries, central venous catheters (CVCs), and prothrombotic chemotherapeutic agents are important risk factors in cancer patients. Recent efforts to improve VTE management in cancer patients are directed toward optimizing prevention during high-risk periods. Prophylaxis with anticoagulants during hospitalizations and the immediate postoperative period is well established, and although extended postoperative prophylaxis for up to 4 weeks is safe, questions remain regarding benefit. Thromboprophylaxis for preventing CVC-related thrombosis is no longer recommended. Research is focusing on using validated risk-assessment models to identify high-risk ambulatory patients who might benefit from thromboprophylaxis during chemotherapy. Although the treatment of cancer-associated VTE is firmly based on the use of low-molecular-weight heparin, questions remain regarding duration of therapy, management of catheter-related thrombosis, use of inferior vena cava filters, and potential therapeutic roles of the newer oral anticoagulants.

Keywords

cancer - venous thrombosis - prevention - treatment
 

  • References

  • 1 Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999; 84 (5) 437-445
    PubMedGoogle Scholar
  • 2 Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost 2003; 29 (3) 247-258
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Brose KMJ, Lee AYY. Cancer-associated thrombosis: prevention and treatment. Curr Oncol 2008; 15 (Suppl. 01) S58-S67
    CrossrefPubMedGoogle Scholar
  • 4 Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost 2011; 9 (Suppl. 01) 316-324
    CrossrefPubMedGoogle Scholar
  • 5 Saber W, Moua T, Williams EC , et al. Risk factors for catheter-related thrombosis (CRT) in cancer patients: a patient-level data (IPD) meta-analysis of clinical trials and prospective studies. J Thromb Haemost 2011; 9 (2) 312-319
    CrossrefPubMedGoogle Scholar
  • 6 Lee AY. Thrombosis in cancer: an update on prevention, treatment, and survival benefits of anticoagulants. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 144-149
    CrossrefPubMedGoogle Scholar
  • 7 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 8 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006; 166 (4) 458-464
    CrossrefPubMedGoogle Scholar
  • 9 Chew HK, Wun T, Harvey DJ, Zhou H, White RH. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007; 25 (1) 70-76
    PubMedGoogle Scholar
  • 10 Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost 2005; 94 (4) 867-871
    PubMedGoogle Scholar
  • 11 Agnelli G, Gussoni G, Bianchini C , et al; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
    CrossrefPubMedGoogle Scholar
  • 12 Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 27 (29) 4885-4888
    CrossrefPubMedGoogle Scholar
  • 13 Rajkumar SV, Jacobus S, Callander NS , et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11 (1) 29-37
    CrossrefPubMedGoogle Scholar
  • 14 Wu CM, Lee AY. A systematic review of the incidence of venous thromboembolism (VTE) and effectiveness of prophylaxis in patients with multiple myeloma (MM) receiving thalidomide. (ASCO meeting abstracts). J Clin Oncol 2007; ;ASCO Annual Meeting Proceedings Part 1, 25(18S)(Suppl June 20):9056
    PubMedGoogle Scholar
  • 15 Sousou T, Khorana A. Inpatient chemotherapy and risk for venous thromboembolism (ASCO meeting abstracts). J Clin Oncol 2007; ;ASCO Annual Meeting Proceedings Part 1, 25(18S)(Suppl June 20):9092
    PubMedGoogle Scholar
  • 16 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 17 Gould MK, Garcia DA, Wren SM , et al. American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e227S-e277S
    CrossrefPubMedGoogle Scholar
  • 18 Lyman GH, Khorana AA, Falanga A , et al. American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25 (34) 5490-5505
    CrossrefPubMedGoogle Scholar
  • 19 Petersen LJ. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines. Cancer Treat Rev 2009; 35 (8) 754-764
    CrossrefPubMedGoogle Scholar
  • 20 Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51 (2–3) 70-78
    CrossrefPubMedGoogle Scholar
  • 21 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17 (Suppl. 03) 304-312
    PubMedGoogle Scholar
  • 22 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84 (8) 1099-1103
    CrossrefPubMedGoogle Scholar
  • 23 McLeod RS, Geerts WH, Sniderman KW , et al. Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. Ann Surg 2001; 233 (3) 438-444
    CrossrefPubMedGoogle Scholar
  • 24 Akl EA, Rohilla S, Barba M , et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer 2008; 113 (7) 1685-1694
    CrossrefPubMedGoogle Scholar
  • 25 Akl EA, Labedi N, Terrenato I , et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database Syst Rev 2011; (11) CD009447
    PubMedGoogle Scholar
  • 26 Agnelli G, Bolis G, Capussotti L , et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006; 243 (1) 89-95
    CrossrefPubMedGoogle Scholar
  • 27 Bergqvist D, Agnelli G, Cohen AT , et al; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13) 975-980
    CrossrefPubMedGoogle Scholar
  • 28 Rasmussen MS, Jorgensen LN, Wille-Jørgensen P , et al. FAME Investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006; 4 (11) 2384-2390
    CrossrefPubMedGoogle Scholar
  • 29 Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P. CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8 (6) 1223-1229
    CrossrefPubMedGoogle Scholar
  • 30 Khorana AA. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients. Oncologist 2007; 12 (11) 1361-1370
    CrossrefPubMedGoogle Scholar
  • 31 Khorana AA, Streiff MB, Farge D , et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27 (29) 4919-4926
    CrossrefPubMedGoogle Scholar
  • 32 Mandalà M, Falanga A, Roila F. ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
    CrossrefPubMedGoogle Scholar
  • 33 Streiff MB. An Overview of the NCCN and ASCO Guidelines on Cancer-Associated Venous Thromboembolism. Cancer Invest 2009; 27 (S1) 41-52
    CrossrefPubMedGoogle Scholar
  • 34 Streiff MB. National Comprehensive Cancer Center Network. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133
    CrossrefPubMedGoogle Scholar
  • 35 Blom JW, Vanderschoot JP, Oostindiër MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006; 4 (3) 529-535
    CrossrefPubMedGoogle Scholar
  • 36 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160 (6) 809-815
    CrossrefPubMedGoogle Scholar
  • 37 Johnson DH, Fehrenbacher L, Novotny WF , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22 (11) 2184-2191
    CrossrefPubMedGoogle Scholar
  • 38 Barlogie B, Tricot G, Anaissie E , et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354 (10) 1021-1030
    CrossrefPubMedGoogle Scholar
  • 39 Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M. Italian Multiple Myeloma Network, Gimema. Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide. J Thromb Haemost 2006; 4 (8) 1842-1845
    CrossrefPubMedGoogle Scholar
  • 40 Scappaticci FA, Skillings JR, Holden SN , et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99 (16) 1232-1239
    CrossrefPubMedGoogle Scholar
  • 41 Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300 (19) 2277-2285
    CrossrefPubMedGoogle Scholar
  • 42 Agnelli G, George DJ, Kakkar AK , et al. SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (7) 601-609
    CrossrefPubMedGoogle Scholar
  • 43 Bohlius J, Wilson J, Seidenfeld J , et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98 (10) 708-714
    CrossrefPubMedGoogle Scholar
  • 44 Reiss H, Pelzer U, Deutschinoff G , et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO-004 trial. J Clin Oncol 2009 ASCO Annual Meeting Proceedings 2009; 27 (June 20 Suppl): LBA4506
    PubMedGoogle Scholar
  • 45 Maraveyas MH, Lofts F, Garadi KK , et al. Chemoanticoagulation versus chemotherapy in advanced pancreatic cancer (APC): Results of the interim analysis of the FRAGEM trial. J Clin Oncol 2007 ASCO Annual Meeting Proceedings 2007; 25 (18S) (June 20 Suppl): 4583
    PubMedGoogle Scholar
  • 46 Maraveyas MH, Roy R, Propper D , et al. Gemcitabine with or without prophylactic weight adjusted dalteparin in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study). Poster presented at: National Cancer Research Institute Conference. 5th NCRI Cancer Conference; 2009 October 4–7; Birmingham, UK:LB112
    PubMedGoogle Scholar
  • 47 Akl EA, Labedi N, Barba M , et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (6) CD006650
    PubMedGoogle Scholar
  • 48 Ay C, Dunkler D, Marosi C , et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
    CrossrefPubMedGoogle Scholar
  • 49 Mandala M, Clerici M, Corradino I , et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the ‘SENDO experience’. Ann Oncol 2012; 23 (6) 1416-1421
    CrossrefPubMedGoogle Scholar
  • 50 Palumbo A, Sezer O, Kyle R , et al. IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009; 23 (10) 1716-1730
    CrossrefPubMedGoogle Scholar
  • 51 Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med 2007; 356 (14) 1438-1444
    CrossrefPubMedGoogle Scholar
  • 52 Barbar S, Noventa F, Rossetto V , et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010; 8 (11) 2450-2457
    CrossrefPubMedGoogle Scholar
  • 53 Samama MM, Cohen AT, Darmon J-Y , et al. Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341 (11) 793-800
    CrossrefPubMedGoogle Scholar
  • 54 Leizorovicz A, Cohen AT, Turpie AGG, Olsson C-G, Vaitkus PT, Goldhaber SZ. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110 (7) 874-879
    CrossrefPubMedGoogle Scholar
  • 55 Cohen AT, Davidson BL, Gallus AS , et al. ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332 (7537) 325-329
    CrossrefPubMedGoogle Scholar
  • 56 Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007; 146 (4) 278-288
    CrossrefPubMedGoogle Scholar
  • 57 Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6 (3) 405-414
    CrossrefPubMedGoogle Scholar
  • 58 Alikhan R, Cohen AT. WITHDRAWN: Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev 2010; (2) CD003747
    PubMedGoogle Scholar
  • 59 Kahn SR, Lim W, Dunn AS , et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e195S-e226S
    CrossrefPubMedGoogle Scholar
  • 60 Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003; 21 (19) 3665-3675
    CrossrefPubMedGoogle Scholar
  • 61 Raad II, Luna M, Khalil SA, Costerton JW, Lam C, Bodey GP. The relationship between the thrombotic and infectious complications of central venous catheters. JAMA 1994; 271 (13) 1014-1016
    CrossrefPubMedGoogle Scholar
  • 62 van Rooden CJ, Schippers EF, Barge RM , et al. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005; 23 (12) 2655-2660
    PubMedGoogle Scholar
  • 63 Kucher N. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med 2011; 364 (9) 861-869
    CrossrefPubMedGoogle Scholar
  • 64 Verso M, Agnelli G, Bertoglio S , et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005; 23 (18) 4057-4062
    CrossrefPubMedGoogle Scholar
  • 65 Abdelkefi A, Ben Othman T, Kammoun L , et al. Prevention of central venous line-related thrombosis by continuous infusion of low-dose unfractionated heparin, in patients with haemato-oncological disease. A randomized controlled trial. Thromb Haemost 2004; 92 (3) 654-661
    PubMedGoogle Scholar
  • 66 Evans RS, Sharp JH, Linford LH , et al. Risk of symptomatic DVT associated with peripherally inserted central catheters. Chest 2010; 138 (4) 803-810
    CrossrefPubMedGoogle Scholar
  • 67 Lee AY, Levine MN, Butler G , et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006; 24 (9) 1404-1408
    CrossrefPubMedGoogle Scholar
  • 68 Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among cancer patients with peripherally inserted central catheters. J Clin Oncol 2002; 20 (15) 3276-3281
    CrossrefPubMedGoogle Scholar
  • 69 Monreal M, Raventos A, Lerma R , et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines—a prospective study. Thromb Haemost 1994; 72 (4) 548-550
    PubMedGoogle Scholar
  • 70 Prandoni P, Bernardi E, Marchiori A , et al. The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study. BMJ 2004; 329 (7464) 484-485
    CrossrefPubMedGoogle Scholar
  • 71 Donayre CE, White GH, Mehringer SM, Wilson SE. Pathogenesis determines late morbidity of axillosubclavian vein thrombosis. Am J Surg 1986; 152 (2) 179-184
    CrossrefPubMedGoogle Scholar
  • 72 Elman EE, Kahn SR. The post-thrombotic syndrome after upper extremity deep venous thrombosis in adults: a systematic review. Thromb Res 2006; 117 (6) 609-614
    CrossrefPubMedGoogle Scholar
  • 73 Akl EA, Vasireddi SR, Gunukula S , et al. Anticoagulation for patients with cancer and central venous catheters. Cochrane Database Syst Rev 2011; (4) CD006468
    PubMedGoogle Scholar
  • 74 Cadman A, Lawrance JA, Fitzsimmons L, Spencer-Shaw A, Swindell R. To clot or not to clot? That is the question in central venous catheters. Clin Radiol 2004; 59 (4) 349-355
    CrossrefPubMedGoogle Scholar
  • 75 Pottecher T, Forrler M, Picardat P, Krause D, Bellocq JP, Otteni JC. Thrombogenicity of central venous catheters: prospective study of polyethylene, silicone and polyurethane catheters with phlebography or post-mortem examination. Eur J Anaesthesiol 1984; 1 (4) 361-365
    PubMedGoogle Scholar
  • 76 Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin 2008; 58 (6) 323-346
    CrossrefPubMedGoogle Scholar
  • 77 Luciani A, Clement O, Halimi P , et al. Catheter-related upper extremity deep venous thrombosis in cancer patients: a prospective study based on Doppler US. Radiology 2001; 220 (3) 655-660
    CrossrefPubMedGoogle Scholar
  • 78 Caers J, Fontaine C, Vinh-Hung V , et al. Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports. Support Care Cancer 2005; 13 (5) 325-331
    CrossrefPubMedGoogle Scholar
  • 79 Verso M, Agnelli G, Kamphuisen PW , et al. Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients. Intern Emerg Med 2008; 3 (2) 117-122
    CrossrefPubMedGoogle Scholar
  • 80 Eastridge BJ, Lefor AT. Complications of indwelling venous access devices in cancer patients. J Clin Oncol 1995; 13 (1) 233-238
    PubMedGoogle Scholar
  • 81 Grove JR, Pevec WC. Venous thrombosis related to peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11 (7) 837-840
    CrossrefPubMedGoogle Scholar
  • 82 Liem TK, Yanit KE, Moseley SE , et al. Peripherally inserted central catheter usage patterns and associated symptomatic upper extremity venous thrombosis. J Vasc Surg 2012; 55 (3) 761-767
    CrossrefPubMedGoogle Scholar
  • 83 Pierce CM, Wade A, Mok Q. Heparin-bonded central venous lines reduce thrombotic and infective complications in critically ill children. Intensive Care Med 2000; 26 (7) 967-972
    CrossrefPubMedGoogle Scholar
  • 84 Dentali F, Gianni M, Agnelli G, Ageno W. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6 (1) 70-75
    PubMedGoogle Scholar
  • 85 Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004; 89 (2) 201-206
    PubMedGoogle Scholar
  • 86 Fijnheer R, Paijmans B, Verdonck LF, Nieuwenhuis HK, Roest M, Dekker AW. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol 2002; 118 (1) 267-270
    CrossrefPubMedGoogle Scholar
  • 87 Bern MM, Lokich JJ, Wallach SR , et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112 (6) 423-428
    CrossrefPubMedGoogle Scholar
  • 88 Boraks P, Seale J, Price J , et al. Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. Br J Haematol 1998; 101 (3) 483-486
    CrossrefPubMedGoogle Scholar
  • 89 Monreal M, Lafoz E, Ruiz J, Valls R, Alastrue A. Upper-extremity deep venous thrombosis and pulmonary embolism. A prospective study. Chest 1991; 99 (2) 280-283
    CrossrefPubMedGoogle Scholar
  • 90 Karthaus M, Kretzschmar A, Kröning H , et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17 (2) 289-296
    PubMedGoogle Scholar
  • 91 Couban S, Goodyear M, Burnell M , et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005; 23 (18) 4063-4069
    CrossrefPubMedGoogle Scholar
  • 92 Agnelli G, Verso M. Therapy Insight: venous-catheter-related thrombosis in cancer patients. Nat Clin Pract Oncol 2006; 3 (4) 214-222
    CrossrefPubMedGoogle Scholar
  • 93 Shivakumar SP, Anderson DR, Couban S. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27 (29) 4858-4864
    CrossrefPubMedGoogle Scholar
  • 94 Akl EA, Vasireddi SR, Gunukula S , et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; 6 (6) CD006649
    PubMedGoogle Scholar
  • 95 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106 (8) 2710-2715
    CrossrefPubMedGoogle Scholar
  • 96 Warkentin TE, Levine MN, Hirsh J , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-1335
    CrossrefPubMedGoogle Scholar
  • 97 Büller HR, Davidson BL, Decousus H , et al. Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349 (18) 1695-1702
    CrossrefPubMedGoogle Scholar
  • 98 Büller HR, Davidson BL, Decousus H , et al. Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140 (11) 867-873
    CrossrefPubMedGoogle Scholar
  • 99 Hull RD, Pineo GF, Brant RF , et al. LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006; 119 (12) 1062-1072
    CrossrefPubMedGoogle Scholar
  • 100 Lee AY, Levine MN, Baker RI , et al. Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2) 146-153
    CrossrefPubMedGoogle Scholar
  • 101 Meyer G, Marjanovic Z, Valcke J , et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002; 162 (15) 1729-1735
    CrossrefPubMedGoogle Scholar
  • 102 Akl EA, Labedi N, Barba M , et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; (6) CD006650
    PubMedGoogle Scholar
  • 103 Wells PS, Anderson DR, Rodger MA , et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165 (7) 733-738
    CrossrefPubMedGoogle Scholar
  • 104 Falck-Ytter Y, Francis CW, Johanson NA , et al. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 105 Louzada ML, Carrier M, Lazo-Langner A , et al. Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 2012; 126 (4) 448-454
    CrossrefPubMedGoogle Scholar
  • 106 Schulman S, Kearon C, Kakkar AK , et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
    CrossrefPubMedGoogle Scholar
  • 107 Bauersachs R, Berkowitz SD, Brenner B , et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
    CrossrefPubMedGoogle Scholar
  • 108 EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW , et al. The EINSTEIN–PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366 (14) 1287-1297
    CrossrefPubMedGoogle Scholar
  • 109 Kearon C, Akl EA, Comerota AJ , et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2) (Suppl): e419S-e494S
    CrossrefPubMedGoogle Scholar
  • 110 Decousus H, Leizorovicz A, Parent F , et al. A clinical trial of vena cava filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338 (7) 409-415
    CrossrefPubMedGoogle Scholar
  • 111 PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005; 112 (3) 416-422
    CrossrefPubMedGoogle Scholar
  • 112 Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev 2010; (2) CD006212
    PubMedGoogle Scholar
  • 113 Nicholson W, Nicholson WJ, Tolerico P , et al. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010; 170 (20) 1827-1831
    CrossrefPubMedGoogle Scholar
  • 114 Chung J, Owen RJ. Using inferior vena cava filters to prevent pulmonary embolism. Can Fam Physician 2008; 54 (1) 49-55
    PubMedGoogle Scholar